Get the Stockscreener App
1.64
0.61%
-0.01
Ovid Therapeutics Inc stock is traded at $1.64, with a volume of 884.10K.
It is down -0.61% in the last 24 hours and up +24.24% over the past month.
Ovid Therapeutics Inc is a biopharmaceutical company that is dedicated to reducing seizures and meaningfully improving the lives of people affected by rare epilepsies and seizure-related neurological disorders. The company has built a differentiated pipeline of medicines with potential first-in-class drug mechanisms of action to treat seizures. This pipeline has produced two epilepsy programs with potential first-in-class mechanisms of action, and one epilepsy program with a potential best-in-class mechanism of action.
See More
Previous Close:
$1.65
Open:
$1.69
24h Volume:
884.10K
Relative Volume:
0.32
Market Cap:
$116.79M
Revenue:
$391.70K
Net Income/Loss:
$-52.34M
P/E Ratio:
-2.1867
EPS:
-0.75
Net Cash Flow:
$-45.92M
1W Performance:
-1.80%
1M Performance:
+24.24%
6M Performance:
+466.89%
1Y Performance:
+54.72%
1-Day Range:
$1.61
$1.71
1-Week Range:
$1.54
$1.71
52-Week Range:
$0.2425
$2.01
Ovid Therapeutics Inc Stock (OVID) Company Profile
Name
Ovid Therapeutics Inc
Sector
Industry
Phone
212-776-4381
Address
441 NINTH AVENUE, 14TH FLOOR, NEW YORK, NY
Compare OVID with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
OVID
Ovid Therapeutics Inc
|
1.64 | 117.50M | 391.70K | -52.34M | -45.92M | -0.75 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.04 | 113.14B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
741.29 | 78.49B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
877.94 | 54.76B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
397.55 | 54.51B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
197.01 | 41.64B | 447.02M | -1.18B | -906.14M | -6.1812 |
Ovid Therapeutics Inc Stock (OVID) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-11-25 | Initiated | Roth Capital | Buy |
| Nov-17-25 | Initiated | Leerink Partners | Outperform |
| Oct-09-25 | Initiated | Oppenheimer | Outperform |
| Aug-08-25 | Resumed | B. Riley Securities | Buy |
| Jun-18-24 | Downgrade | Oppenheimer | Outperform → Perform |
| Apr-30-24 | Initiated | B. Riley Securities | Buy |
| Apr-29-24 | Initiated | H.C. Wainwright | Buy |
| Apr-05-24 | Initiated | Wedbush | Outperform |
| Dec-21-23 | Initiated | BTIG Research | Buy |
| Oct-13-23 | Initiated | Oppenheimer | Outperform |
| Apr-20-21 | Downgrade | Cantor Fitzgerald | Buy → Neutral |
| Mar-03-21 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Dec-02-20 | Downgrade | Citigroup | Buy → Neutral |
| Dec-02-20 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| Sep-04-19 | Initiated | RBC Capital Mkts | Outperform |
| Apr-20-18 | Initiated | Ladenburg Thalmann | Buy |
View All
Ovid Therapeutics Inc Stock (OVID) Latest News
Aug Big Picture: How analysts rate Ovid Therapeutics Inc stock todayWeekly Loss Report & Technical Confirmation Alerts - moha.gov.vn
Janus Henderson Group PLC Acquires Significant Stake in Ovid Therapeutics Inc - GuruFocus
Roth Capital Initiates Coverage on Ovid Therapeutics (NASDAQ:OVID) - MarketBeat
Ovid Therapeutics shareholders approve increase in authorized shares and related proposals - Investing.com
Ovid Therapeutics shareholders approve increase in authorized shares and related proposals By Investing.com - Investing.com South Africa
Ovid Therapeutics Stockholders Approve Key Proposals - TipRanks
Roth Capital Initiates Coverage of Ovid Therapeutics (OVID) with Buy Recommendation - Nasdaq
Roth/MKM initiates Ovid Therapeutics stock with Buy rating on epilepsy drug - Investing.com Canada
OVID: Roth Capital Initiates Coverage with a "Buy" Rating at $3. - GuruFocus
What analysts say about Ovid Therapeutics Inc stockTrading Volume Surges & Capitalize On Fast Trends - earlytimes.in
Will Ovid Therapeutics Inc. stock deliver long term returns - Newser
Will Ovid Therapeutics Inc. (1OT) stock see valuation expansionEarnings Recap Report & Low Risk High Win Rate Stock Picks - Newser
Will Ovid Therapeutics Inc. (1OT) stock gain from lower interest ratesPortfolio Performance Summary & Weekly Market Pulse Alerts - Newser
Minerva jumps on phase III funding, leading neuro stocks - BioWorld MedTech
Will Ovid Therapeutics Inc. stock gain from strong economyDividend Hike & Precise Entry and Exit Recommendations - Newser
Will Ovid Therapeutics Inc. (1OT) stock benefit from sector leadershipJuly 2025 Opening Moves & Verified Chart Pattern Signals - Newser
Is Ovid Therapeutics Inc. (1OT) stock attractive for growth fundsJuly 2025 Final Week & Growth-Oriented Investment Plans - Newser
Ovid Therapeutics appoints Petra Kaufmann as chief medical officer By Investing.com - Investing.com Nigeria
Ovid Therapeutics Names Petra Kaufmann Chief Medical Officer - marketscreener.com
Ovid Therapeutics appoints Petra Kaufmann as chief medical officer - Investing.com
Ovid Therapeutics Appoints Dr. Petra Kaufmann as Chief Medical Officer - Enidnews.com
How Ovid Therapeutics Inc. (1OT) stock correlates with oil marketsProduct Launch & Real-Time Chart Pattern Alerts - Newser
Is Ovid Therapeutics Inc. (1OT) stock dividend growth reliableMarket Trend Review & Free Real-Time Volume Trigger Notifications - Newser
IPO Launch: Is Ovid Therapeutics Inc stock positioned well for digital economyWeekly Gains Summary & Weekly Stock Performance Updates - moha.gov.vn
November 2025's Top Penny Stock Opportunities - simplywall.st
HC Wainwright Has Negative Estimate for OVID FY2025 Earnings - MarketBeat
What analysts say about Ovid Therapeutics Inc 1OT stockVolume Profile Analysis & Explosive Profit Growth - earlytimes.in
Ovid Therapeutics (OVID): HC Wainwright Raises Price Target to $2.00 | OVID Stock News - GuruFocus
HC Wainwright & Co. Maintains Ovid Therapeutics (OVID) Buy Recommendation - Nasdaq
Ovid CEO Meg Alexander Takes The Helm In Time To Harvest Growing Blooms - Citeline News & Insights
Is Ovid Therapeutics Inc. stock overvalued by current metricsJuly 2025 Highlights & Real-Time Market Sentiment Alerts - newser.com
Ovid Therapeutics (NASDAQ:OVID) Receives Consensus Recommendation of "Buy" from Analysts - MarketBeat
Equities Analysts Issue Forecasts for OVID Q4 Earnings - MarketBeat
Visual trend scoring systems applied to Ovid Therapeutics Inc.Earnings Risk Summary & Detailed Earnings Play Alerts - newser.com
What consensus target says about Ovid Therapeutics Inc. (1OT) stock2025 Growth vs Value & Risk Managed Investment Entry Signals - newser.com
Is Ovid Therapeutics Inc. stock cheap at current valuation2025 Market Outlook & Expert Curated Trade Setups - newser.com
Regression analysis insights on Ovid Therapeutics Inc. performanceDollar Strength & High Yield Equity Trading Tips - newser.com
Ovid Therapeutics Reports Q3 2025 Financial Results - MSN
Combining machine learning predictions for Ovid Therapeutics Inc. - newser.com
Long term hold vs stop loss in Ovid Therapeutics Inc.2025 Short Interest & Community Trade Idea Sharing - newser.com
Ovid Therapeutics Inc Stock (OVID) Financials Data
Revenue
Net Income
Cash Flow
EPS
Ovid Therapeutics Inc Stock (OVID) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Rona Jeffrey A | CBFO |
Feb 26 '25 |
Sale |
0.56 |
3,902 |
2,185 |
67,973 |
| ALEXANDER MARGARET A. | President and COO |
Jan 27 '25 |
Buy |
0.73 |
6,810 |
4,971 |
34,935 |
1.08%
0.91%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):